A Study of Lipid Metabolism and Mitochondrial Function in Myeloid Cells and Total Aortic Tissue in Patients With Ascending Thoracic Aortic Aneurysm (ATA) and Bicuspid (BA) or Tricuspid (TA) Aortic Valves.

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire Dijon

About this trial

Ascending aortic aneurysms (AAAs) are serious conditions that can lead to aortic dissections or ruptures, carrying a high risk of mortality. Their pathophysiology is based on complex mechanisms involving inflammatory and metabolic processes, as well as alterations in mitochondrial function. The presence of a bicuspid aortic valve (BAV) or tricuspid aortic valve (TAV) significantly influences the progression and severity of aneurysms. Bicuspid aortic valve (BAV) patients often develop aortic aneurysms earlier, as early as age 40-50, whereas tricuspid aortic valve (TAV) patients generally present with a degenerative condition that appears later (after age 50). The objective of this study is to compare the inflammatory, metabolic, and transcriptomic signatures of myeloid cells and total aortic tissue between BAV and TAV patients. These analyses will help identify specific molecular mechanisms, potential biomarkers, and therapeutic targets. To ensure pathophysiological homogeneity, patients with aneurysms of genetic origin (Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, etc.) will be excluded.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Individuals who have given their consent

Patients with an ascending aortic aneurysm for which surgical replacement is indicated

Age > 18 years

Scheduled surgery

Disqualifiers

A person subject to a legal protective measure (guardianship, conservatorship)

A person subject to a judicial safeguard measure - A pregnant woman, a woman in labor, or a breastfeeding woman

Adults who are legally incapacitated or unable to give consent

Emergency surgical procedures

Trial population

Patients with ascending aortic aneurysms

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Additional blood samples

    Procedure/Surgery

    Additional blood sample are collected at the time of routine clinical blood sampling for recherche analyses.

  • Collection of discarded ascending aortic tissue

    Procedure/Surgery

    The aneurysmal portion of the ascending aorta (surgical specimen), which would otherwise be discarded, is collected for research purposes. No other tissue is collected, and the research protocol does not alter the surgical procedure.

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: Patient with an ascending aortic aneurysm and a bicuspid aortic valve (BAV)2 interventions
Group B: Patient with an ascending aortic aneurysm and a tricuspid aortic valve (TAV)2 interventions

Trial outcomes

Primary outcomes

1

Inflammatory, metabolic, and transcriptomic markers of myeloid cells and aortic tissue

Time frame
At the time of surgery

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.